Investment Rating - The report maintains a "Recommendation" rating for Ganli Pharmaceutical (603087.SH) [1][8] Core Views - The company's main business is steadily increasing, with significant growth in both domestic and international markets. The domestic revenue reached 1.845 billion yuan, a year-on-year increase of 55.28%, while international revenue was 222 million yuan, growing by 75.08% [4][8] - The company is actively expanding its international presence and has received approvals for its products in several countries, including Malaysia, Pakistan, and Argentina [8] - The report highlights the successful implementation of insulin procurement strategies, which have led to both volume and price increases for insulin products [7][8] - The company is advancing its innovation pipeline, particularly in the GLP-1 segment, with several products in various stages of clinical trials [7][8] Summary by Sections Financial Performance - In the first half of 2025, the company achieved operating revenue of 2.067 billion yuan, a year-on-year increase of 57.18%, and a net profit attributable to shareholders of 604 million yuan, up 101.96% [4] - The projected operating revenues for 2025-2027 are 4.173 billion yuan, 5.226 billion yuan, and 6.201 billion yuan, respectively, with year-on-year growth rates of 37.0%, 25.2%, and 18.7% [6][9] - The net profit for the same period is expected to be 1.207 billion yuan, 1.530 billion yuan, and 1.834 billion yuan, with growth rates of 96.4%, 26.7%, and 19.9% [6][9] Market Strategy - The company has successfully expanded its market share through two rounds of insulin procurement, achieving a 32.6% increase in procurement agreement volume for the upcoming 2024 procurement [7] - The report emphasizes the importance of innovation in the company's growth strategy, particularly in the development of new drug formulations and clinical trials [7][8] International Expansion - The international revenue growth reflects the company's successful entry into new markets and the approval of its products in various countries [8] - The report notes that the company has achieved a significant milestone with the approval of its insulin production technology in Brazil, marking a key step in its international strategy [8]

Investment Rating - The industry investment rating is "Outperform the Market" [1][47]. Core Insights - The white spot market for vitiligo treatment is vast, with a potential market size expected to reach 21.7 billion yuan by 2030, driven by an increasing number of patients and the need for effective treatments [3][15][39]. - Current treatment options are inadequate, with no approved products specifically for vitiligo in China, highlighting a significant gap in the market that innovative drugs could fill [3][26]. - The competitive landscape is favorable, with several small pharmaceutical companies and leading firms vying for market share, and key products expected to receive approval soon [3][39]. Summary by Sections Part 1: Patient Demographics and Health Risks - The prevalence of vitiligo is significant, with approximately 22.83 million patients in China, of which 54.01% are receiving treatment [3][15]. - The condition is associated with severe psychological impacts, including a higher incidence of depression among patients [3][10]. Part 2: Current Treatment Limitations - Existing treatments, primarily involving drug therapy and phototherapy, have shown limited effectiveness, necessitating the introduction of new drugs with higher repigmentation rates [3][24]. - The current market lacks approved medications specifically for vitiligo, with existing drugs primarily approved for other conditions [3][26]. Part 3: Competitive Landscape and Drug Development - The vitiligo treatment sector is characterized by a lack of approved products, with several drugs in various stages of clinical trials, including one in Phase III and six in Phase II [3][39]. - JAK inhibitors are identified as key targets in drug development, with the first approved topical JAK1/JAK2 inhibitor, Ruxolitinib cream, showing promising sales growth [3][32][39]. - The innovative drug market for vitiligo is projected to reach 10 billion yuan, with significant interest in companies like Kangzheng Pharmaceutical and TianKang [3][39]. Part 4: Investment Recommendations - The report suggests focusing on the progress of drug development in the vitiligo sector and monitoring companies involved, including Kangzheng Pharmaceutical, TianKang, Huadong Medicine, and others [3][39].

Investment Rating - The report maintains a "Recommendation" rating for the company [1][8] Core Views - The company achieved a revenue of 8.56 billion yuan in the first half of 2025, representing a year-on-year increase of 6.4%, and a net profit of 1.1 billion yuan, up 45.4% year-on-year [5][8] - The product structure is continuously optimized, with sales volume increasing by 2.0% year-on-year, outperforming the industry average [8] - The company is expected to enhance its profitability due to the continued growth of mid-to-high-end products and effective cost control measures [8] Financial Performance Summary - In 2Q25, the company reported revenue of 4.73 billion yuan, a year-on-year increase of 6.1%, and a net profit of 0.94 billion yuan, up 43.0% year-on-year [5][8] - The company’s gross margin for 2Q25 was 47.7%, with a net profit margin of 19.8%, reflecting an improvement of 5.1 percentage points year-on-year [8] - The forecast for net profit for 2025-2027 has been adjusted to 1.47 billion, 1.77 billion, and 2.04 billion yuan respectively [8] Market and Product Insights - The company’s beer sales in the first half of 2025 were 2.352 million kiloliters, with an average price of 3,358 yuan per kiloliter, indicating a price increase of 4.8% year-on-year [8] - Revenue from mid-to-high-end products reached 5.54 billion yuan, up 9.3% year-on-year, while ordinary products generated 2.36 billion yuan, up 1.6% year-on-year [8] - The company is expanding its market presence, with significant revenue growth in various regions, particularly in East China, which saw a 20.5% increase [8]

Investment Rating - The industry investment rating is "stronger than the market" (预计6个月内，行业指数表现强于市场表现5%以上) [35] Core Viewpoints - The report emphasizes the importance of multi-party collaboration in supporting the development of innovative drugs and medical devices, highlighting the integration of data, policy, and funding as essential elements for growth [4] - The report notes that recent measures from the Financial Supervisory Administration and the Medical Insurance Bureau aim to promote the development of commercial health insurance, which will provide additional support for the innovation and development of drugs and medical devices [4] Summary by Sections Industry Insights - The Medical Insurance Bureau's recent meetings have established a comprehensive support system for innovative drugs and medical devices, involving various stakeholders such as research institutions, enterprises, medical institutions, financial companies, and government departments [4] - The Financial Supervisory Administration has released measures to enhance the quality of commercial health insurance, which will further support the biopharmaceutical industry's innovation [4] Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipelines, such as 恒瑞医药 (Hengrui Medicine), 百济神州 (BeiGene), and 中国生物制药 (China Biologic Products) [6] - It also highlights companies with significant single-product potential and those leading in advanced technology platforms, recommending关注 (focus on) companies like 凯莱英 (Kailaiying) and 药明康德 (WuXi AppTec) [6] Market Performance - The pharmaceutical sector experienced a decline of 0.84% last week, ranking last among 28 industries, while the Shanghai and Shenzhen 300 Index rose by 1.23% [9][21] - The report indicates that the pharmaceutical sector's valuation is currently at 30.91 times (TTM), with a premium of 37.32% compared to the overall A-shares excluding financials [27]

证券研究报告 海外策略周报： 市场继续交易降息预期 证券分析师 魏 伟 投资咨询资格编号：S1060513060001 、BOT313 陈 骁 投资咨询资格编号：S1060516070001 、BWH863 郝博韬 投资咨询资格编号：S1060521110001 请务必阅读正文后免责条款 2025 年 8 月11 日 1 ※ 核心观点 2 • 海外方面，本周市场继续交易降息预期，美股上涨、美元下跌、美债收益率低位震荡后略有反弹。本周降息预期持续发酵，美国 关税2.0落地，全球主要股指多数收涨。本周MSCI全球股指上涨2.52%，标普500、纳指分别上涨2.43%、3.87%；10年期、2年期 美债收益率分别上涨4bp、7bp至4.27%、3.76%；美元指数下跌0.43%至98.3；COMEX黄金、ICE布油分别上涨1.24%、下跌 4.60%。港股方面，国内"反内卷"政策延续，恒生指数继续上涨。国内方面，工信部等八部门发布《机械工业数字化转型实施方 案》，推动AI与智能制造深度融合；央行、工信部等七部门联合印发《关于金融支持新型工业化的指导意见》，明确支持重点行 业防止"内卷式"竞争，推动产业合理布局。本周 ...

1. Report Industry Investment Rating - Not provided in the content 2. Core View of the Report - The performance of ETF products has varied in the past two weeks. Among the major broad - based ETFs, the CSI 2000 ETF had the largest increase, and among the industry and theme products, the military industry ETF had the largest increase. The fund flow trends of different types of ETFs have also changed, with some showing accelerated inflows, some turning from inflows to outflows, and others showing a slowdown in inflows [2][9]. 3. Summary According to the Table of Contents 3.1 ETF Market Review 3.1.1 Main Type ETF Fund Flow Overview - **Return Performance**: As of August 8, in the past two weeks, ETF products showed mixed performance. Among the major broad - based ETFs, the CSI 2000 ETF had the largest increase, and among the industry and theme products, the military industry ETF had the largest increase [9]. - **Fund Flow**: In the past two weeks, among the major broad - based ETFs, the CSI 2000 ETF had a net inflow of funds, while the CSI 300 ETF had the largest net outflow of funds [9]. 3.1.2 Main Type ETF Cumulative Fund Flow - **Broad - based ETF**: Since 2025, the fund flow of major broad - based ETFs has changed from outflow to inflow and then to outflow. The A - series ETFs have had continuous outflows. As of August 8, the Science and Technology/Innovation ETFs, A - series ETFs, and CSI 500 ETFs have all had net outflows. In the past two weeks, the net outflow speed of broad - based ETFs has accelerated, except for the A - series ETFs, whose net outflow speed has slowed down [10]. - **Industry and Theme/Strategy ETF**: The technology ETF has seen an increase in the inflow speed in the past two weeks. The pharmaceutical ETF has turned from net outflow to net inflow, the new energy ETF has turned from net inflow to net outflow, and the consumer ETF has seen an accelerated inflow. The inflow speed of the dividend, cycle, financial real estate, and large - manufacturing ETFs has slowed down [2][14]. - **Bond ETF**: In 2025, the credit bond and treasury bond ETFs have had the largest net inflows. In the past two weeks, there has been a large inflow of funds into the credit bond ETF, the local bond ETF has turned from net outflow to net inflow, the net inflow speed of the treasury bond ETF has slowed down, and the convertible bond and short - term financing ETFs have seen an accelerated net inflow [14]. 3.1.3 ETF Product Structure Distribution - **Newly Established Products**: As of August 8, a total of 13 new ETFs have been established in the market in the past two weeks, with a total issuance share of 5.152 billion, all of which are stock ETFs [2][17]. - **Scale Change**: Compared with the end of 2024, the scale of various types of ETFs has increased. The scale of bond ETFs, commodity ETFs, industry + dividend ETFs, QDII - ETFs, and broad - based ETFs has increased by 204.20%, 106.93%, 45.79%, 22.68%, and 2.55% respectively [2]. 3.1.4 Manager Scale Distribution - As of August 8, Huaxia Fund has the largest on - exchange ETF scale, reaching 79.1655 billion yuan. E Fund's ETF management scale has expanded by nearly 30 billion yuan compared with a year ago [18]. 3.2 Classification - based ETF Tracking 3.2.1 Technology Theme ETF Tracking - **Return Performance**: Products tracking communication equipment - related indices have performed well in the past two weeks [24]. - **Fund Flow**: Products tracking the Hang Seng Technology index had the largest net inflow of funds in the past two weeks, while products tracking the animation and game index had a net outflow of funds [27]. 3.2.2 Dividend Theme ETF Tracking - **Return Performance**: ETF products tracking the Hong Kong Stock Connect High - Yield Selection index had the largest increase in yield in the past two weeks [30]. - **Fund Flow**: Products tracking the S&P China A - Share Large - Cap Dividend Low - Volatility 50 index had the largest net inflow of funds in the past two weeks, while products tracking the Guoxin Hong Kong Stock Connect Central Enterprise Dividend index had a net outflow of funds [34]. 3.2.3 Consumption Theme ETF Tracking - **Return Performance**: Products tracking the China Education index have performed well in the past two weeks, and products tracking the S&P 500 Consumer Select Index have a relatively high premium rate [37]. - **Fund Flow**: ETFs tracking the 800 Consumption index had the largest net inflow of funds in the past two weeks, while products tracking household appliances had a net outflow of funds [40]. 3.2.4 Pharmaceutical Theme ETF Tracking - **Return Performance**: Products tracking innovation - drug indices such as the Hang Seng Innovation - Drug index have performed well in the past two weeks [42]. - **Fund Flow**: Not fully provided in the content 3.3 Hot - Theme ETF Tracking - Not fully provided in the content

Key Points Summary Group 1: U.S. Pension Policy Changes - The Trump administration signed an executive order on August 7 to ease restrictions on alternative investments in 401(k) accounts, including private equity, real estate, and cryptocurrencies. This move aims to enhance retirement savings opportunities for individuals [1][5][6] - The order directs the Secretary of Labor to review guidelines regarding fiduciary responsibilities related to alternative asset investments in 401(k) plans, indicating a potential shift in regulatory stance [5][6] - There are concerns that relaxing investment restrictions may lead to increased management fees, reduced transparency, and liquidity issues, despite the potential for greater investment flexibility [1][5] Group 2: Argentina's Pension Policy - On August 4, Argentine President Milei vetoed a law aimed at increasing pensions for the elderly and disabled, citing fiscal sustainability as the reason for the decision. This move affects a significant portion of the population, as over 40% of jobs in Argentina are informal and many are excluded from the national pension system [2][6][7] - The government argues that increasing pensions would jeopardize efforts to achieve fiscal balance, with projected additional costs of $5 million this year and $12 million by 2026 [7] Group 3: China's Social Security Policy - On August 1, the Supreme People's Court of China clarified that social insurance contributions are mandatory, reinforcing the legal framework around labor disputes and social security compliance [8][10] Group 4: International Pension Developments - Germany is considering comprehensive reforms to strengthen its occupational pension system, which may include expanding the applicability of the "social partner model" to non-collectively bargained employers [11][12] - Norway's sovereign wealth fund, GPFG, is reviewing its investments in Israel following public outcry over its holdings in a military-related company, indicating a focus on ethical investment practices [12][13] - Harvard and Brown University endowment funds have increased their exposure to Bitcoin ETFs, reflecting a growing interest among traditional institutions in cryptocurrency investments [15][16] Group 5: U.S. Independent Contractor Retirement Benefits - Republican senators have proposed the "Independent Retirement Fairness Act" to establish a portable benefits system for independent contractors, allowing employers to voluntarily contribute to retirement accounts, which could enhance retirement security for this growing workforce [17][20] - The proposal aims to balance flexibility and basic welfare protections for independent contractors, amidst ongoing debates about their classification and benefits [18][20] Group 6: U.K. Sustainability Reporting - The U.K. Financial Conduct Authority (FCA) plans to simplify sustainability reporting requirements for asset managers and insurers, aiming to reduce compliance burdens while enhancing transparency [20][21] Group 7: New York City Pension System Performance - New York City's pension systems achieved a 10.3% investment return for the fiscal year 2024, exceeding the actuarial target of 7%, which is expected to save approximately $2.18 billion in pension contributions over the next five years [22][23]

Investment Rating - The industry investment rating is "Outperform the Market" [1][8]. Core Insights - The establishment of the New Tibet Railway Company marks the initiation of significant infrastructure projects, which is expected to boost demand for construction materials, particularly cement and waterproof products [1][7]. - The New Tibet Railway is a crucial link between Xinjiang and Tibet, with a total length of approximately 2000 kilometers, and is projected to require an average of 500 million tons of cement annually during its construction [6][7]. - Major engineering projects are set to commence, indicating a continued push in infrastructure development, which is likely to benefit leading cement companies in the region [6][7]. Summary by Sections Industry Overview - The New Tibet Railway Company has been established with a registered capital of 95 billion RMB, focusing on various construction and transportation services [1][3]. - The railway project has been in planning since 2008 and is part of China's broader transportation network strategy [6]. Project Impact - The New Tibet Railway is expected to directly drive approximately 40 million tons of cement demand, with a construction period estimated at eight years [6][7]. - Key cement companies such as Tianshan Co., Qingsong Jianhua, and others are positioned to benefit from this infrastructure development [6][7]. Future Outlook - The recent launch of the Yaxia Hydropower Project and the establishment of the New Tibet Railway Company suggest a potential increase in construction activity, which will likely enhance the demand for building materials [7]. - The report recommends monitoring companies like Huaxin Cement, Conch Cement, and others for potential investment opportunities as infrastructure projects gain momentum [7].

Investment Rating - The industry investment rating is "Outperform the Market" [1][21] Core Viewpoints - The food and beverage industry is currently experiencing a performance window, with a recommendation to focus on high-growth sectors [1] - The industry has shown a cumulative increase of 0.75% this week, with notable stock performances from Ximai Food (+10.32%), Jinzi Ham (+9.38%), and Ziyan Food (+7.56%) [2][5] - The report suggests identifying stocks with strong earnings certainty during the interim report period, recommending Dongpeng Beverage and highlighting opportunities in dairy products driven by child-rearing subsidy policies [2] Summary by Sections Market Review - The food and beverage sector has seen a cumulative increase of 0.75% this week, with the top three gainers being Ximai Food (+10.32%), Jinzi Ham (+9.38%), and Ziyan Food (+7.56%) [2][5] - The bottom five performers include Panda Dairy (-3.17%), Jindawei (-3.18%), and Sunshine Dairy (-13.54%) [2][5] Investment Recommendations - Focus on companies with strong earnings visibility, recommending Dongpeng Beverage and suggesting attention to Guoquan, Weilong, and Yanjinpuzi [2] - Highlighting investment opportunities in dairy products, recommending Yili and Miaokelan, while suggesting attention to New Dairy [2] - Anticipating a fundamental turnaround in the restaurant supply chain, recommending Anji Food, Qianwei Central Kitchen, and Haitian Flavoring [2] Key Company Announcements - Company announcements include financial results from major players like Tongchen Beijian, which reported a revenue decline of 23.43% year-on-year [7] - Other companies like Guifaxiang and Huoshanghuo also reported revenue declines, while Keming Food showed a significant increase in pig sales year-on-year [7][8] Raw Material Price Tracking - The average price of fresh milk in major production areas is 3.03 yuan/kg, down 5.60% year-on-year, indicating a downward cycle that alleviates cost pressures for dairy producers [9][11] - Prices for major agricultural products such as imported barley and palm oil have shown mixed trends, with palm oil increasing by 13.9% year-on-year [9][12] Company Earnings Forecasts and Ratings - Key companies are rated with recommendations, including Dongpeng Beverage with a projected EPS of 6.40 yuan for 2025 and a PE ratio of 35.3 [19] - Other recommended companies include Yili, Miaokelan, and Anji Food, with respective earnings forecasts and ratings indicating strong future performance [19]

Group 1: US Economic Policy - Trump signed an executive order imposing an additional 25% tariff on Indian goods, raising the total tariff rate to 50%[1] - The US trade deficit in June shrank significantly by 16% to $60.2 billion, the lowest level since September 2023[1] - The probability of a 25 basis point rate cut in September increased from 80.3% to 88.9%[1] Group 2: Economic Indicators - The ISM non-manufacturing index for July fell from 50.8 to 50.1, below the expected 51.5[1] - The GDPNow model predicts a 2.5% annualized growth rate for Q3 2023[1] - Initial jobless claims rose to 226,000, the highest level in a month, exceeding economists' expectations[1] Group 3: Global Economic Trends - Eurozone's composite PMI for July rose to 50.9, a four-month high, but below the initial estimate of 51[1] - The Bank of England cut rates by 25 basis points to 4%, aligning with market expectations[1] - Japan's nominal wages increased by 2.5% year-on-year in June, up from a revised 1.4% the previous month[1] Group 4: Market Reactions - Global stock markets showed recovery, with the S&P 500, Dow Jones, and Nasdaq rising by 2.4%, 1.3%, and 3.9% respectively[1] - Gold prices increased by 1.4%, while Brent and WTI crude oil prices fell by 4.4% and 5.1% respectively[1] - The US dollar index declined by 0.43% to 98.27, influenced by concerns over the job market and rate cut expectations[1]